secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vir Biotechnology, Inc. (VIR)
CIK:        0001706431
Form:       8-K
Filed at:   2023-02-13T23:59:59+00:00
Accession:  0001193125-23-035908
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Vir Bio amends GSK deal: regains full rights to vaccine program, narrows antibody program
--------------------------------------------------------------------------------

- Amendments remove CoV Vaccine Program from collaboration; Vir retains rights to progress independently.
- CoV Antibody Program narrowed to only sotrovimab and VIR-7832; all other antibodies revert to Vir.
- Vir pays tiered royalties in low single digits on vaccine sales, low-to-mid single digits on terminated antibodies.
- Amendments effective March 31, 2022 (vaccine wind-down) and February 8, 2023 (antibody scope reduction).
- GSK retains 50:50 profit share on sotrovimab and VIR-7832 under original DCA terms.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1706431/000119312523035908/0001193125-23-035908-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1706431/000119312523035908/d449379d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-035908

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer